Home / Recalls / Hospira Inc., A Pfizer Company / D-0480-2017

D-0480-2017 Class II Terminated

Recalled by Hospira Inc., A Pfizer Company — Lake Forest, IL

FDA drug recall D-0480-2017 was initiated by Hospira Inc., A Pfizer Company on February 10, 2017 and is designated Class II. Reason for recall: Lack of Sterility Assurance: customer report of leaking bag The recall status is terminated (terminated April 3, 2019). Affected quantity: 578,784 bags.

Recall Details

Product Type: Drugs
Report Date: March 1, 2017
Initiation Date: February 10, 2017
Termination Date: April 3, 2019
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 578,784 bags

Product Description

METRONIDazole Injection, USP 500 mg (5 mg/mL) in 100 mL Single Dose Flexible Container, Rx only, For IV Use, Hospira Inc., Lake Forest, IL --- NDC 0409-7811-24

Reason for Recall

Lack of Sterility Assurance: customer report of leaking bag

Distribution Pattern

Nationwide and Puerto Rico

Code Information

Lot: 54-054-JT, 6/1/2017

Other recalls by Hospira Inc., A Pfizer Company

D-0980-2017 Class III — Argatroban Injection, 250 mg/2.5 mL (100 mg/mL), 5 mL Single-use vial, Rx Only, (July 6, 2017)
D-0898-2017 Class II — Levophed norepinephrine bitartrate, injection, USP, 4 mg /4 mL (1 mg/mL),Rx only (May 18, 2017)
D-0638-2017 Class I — Vancomycin Hydrochloride for Injection, USP, 10 grams, Pharmacy Bulk Package - N (January 24, 2017)
Z-1682-2017 Class II — Plum 360 Infusion Pump, Software Version 15.02. The infusion pump is capable of (December 30, 2016)
D-0096-2017 Class II — Marcaine 0.25% (bupivacaine HCl) injection, USP, 125 mg/50 mL (2.5 mg/mL), 50 mL (September 16, 2016)
D-0097-2017 Class II — Marcaine 0.5% (bupivacaine HCl) injection, USP, 250 mg/50 mL (5 mg/mL), 50 mL Mu (September 16, 2016)
D-0218-2017 Class I — Bupivacaine Hydrochloride Inj., USP (2.5 mg/mL) 0.25%, packaged in 30 mL Single- (August 4, 2016)
Z-2790-2016 Class II — Hospira MedNet Medication Management Suite software, version 6.1, List Numbers 1 (July 28, 2016)